XML 78 R50.htm IDEA: XBRL DOCUMENT v3.20.4
Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2020
USD ($)
Jun. 30, 2019
USD ($)
May 31, 2018
USD ($)
Jul. 31, 2017
USD ($)
Apr. 30, 2016
USD ($)
Agreement
Target
AccountingUnit
Jun. 30, 2018
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Mar. 31, 2017
Target
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized from collaborative arrangement             $ 100,362,000 $ 57,489,000 $ 59,502,000  
Type of Revenue [Extensible List]               us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember  
Deferred revenue             261,130,000 $ 230,239,000    
AbbVie Ireland Unlimited Company                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Milestone payment received     $ 21,000,000.0              
Revenue recognized from collaborative arrangement           $ 9,900,000 $ 38,200,000 $ 5,900,000 $ 19,000,000.0  
Type of Revenue [Extensible List]           us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember  
AbbVie Ireland Unlimited Company | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received         $ 30,000,000.0          
Milestone payment received         14,000,000.0          
Total transaction price         39,800,000          
Estimated sublicense fees         $ 4,200,000          
Number of accounting units | AccountingUnit         2          
AbbVie Ireland Unlimited Company | Collaborative Arrangement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of collaboration agreements | Agreement         2          
Percentage of net profits or net losses related to development and commercialization costs         35.00%          
Amount due from agreement             $ 0 $ 0    
AbbVie Ireland Unlimited Company | CD71 Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received         $ 20,000,000.0          
Milestone payment received $ 40,000,000.0   21,000,000.0 $ 14,000,000.0            
Milestone payment received     21,000,000.0              
Deferred revenue             25,200,000 20,000,000.0    
AbbVie Ireland Unlimited Company | CD71 Agreement | Transferred over Time                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Revenue recognized from collaborative arrangement $ 26,600,000                  
Type of Revenue [Extensible List] us-gaap:LicenseAndServiceMember                  
AbbVie Ireland Unlimited Company | CD71 Agreement | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received         20,000,000.0          
Total transaction price         29,800,000          
Estimated sublicense fees         4,200,000          
Milestone payment received         $ 14,000,000.0          
AbbVie Ireland Unlimited Company | CD71 Agreement | U.S                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Profit split on U.S. sales         35.00%          
AbbVie Ireland Unlimited Company | CD71 Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contingent payments receivable upon achieving development, regulatory and commercial milestones         $ 470,000,000.0          
AbbVie Ireland Unlimited Company | Seattle Genetics Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Sublicense fees paid     $ 4,000,000.0 $ 1,000,000.0            
AbbVie Ireland Unlimited Company | Seattle Genetics Agreement | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Sublicense fees paid         1,000,000.0          
AbbVie Ireland Unlimited Company | Discovery Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received         10,000,000.0          
Number of targets selected | Target                   1
Revenue recognition upon performance obligation         10,000,000.0          
Deferred revenue             $ 8,000,000.0 $ 11,600,000    
AbbVie Ireland Unlimited Company | Discovery Agreement | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received         10,000,000.0          
Total transaction price         $ 10,000,000.0          
AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Milestone payments received   $ 10,000,000.0                
AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target | ASC 606                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total transaction price   $ 10,000,000.0                
Estimated research service period   5 years                
AbbVie Ireland Unlimited Company | Discovery Agreement | Maximum                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Number of targets | Target         2          
AbbVie Ireland Unlimited Company | Discovery Agreement | Maximum | Development, Regulatory and Commercial Milestone Payments                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Contingent milestone payments receivable         $ 265,000,000.0